Dark
Light
Today: July 21, 2024
January 8, 2024
1 min read

nullJPM24: Unveiling San Francisco’s Sizzling ADCs as Hottest Tickets!”

TLDR:

According to a new report from J.P. Morgan, antibody-drug conjugates (ADCs) were the hottest ticket in the biopharma industry in 2023, driving a spike in licensing deal proceeds. Despite a decrease in overall deal flow, licensing deals, venture investments, M&A, and IPOs stayed fairly high thanks to a flurry of late-stage tie-ups. Biopharma licensing partnerships accounted for $63 billion in total value, with one deal alone accounting for $22 billion. Venture investments closed out the year with $17 billion across 250 rounds, while M&A totaled $128.8 billion across 112 acquisitions. The report highlights the potential for smaller biopharmas to find licensing partners, as large companies are offering larger upfront payments for these deals.

Key Points:

  • ADCs drove a spike in licensing deal proceeds in 2023
  • Licensing deals, venture investments, M&A, and IPOs stayed fairly high thanks to late-stage tie-ups
  • Biopharma licensing partnerships accounted for $63 billion in total value
  • Venture investments closed out the year at $17 billion across 250 rounds
  • M&A totaled $128.8 billion across 112 acquisitions
  • Large companies are offering larger upfront payments for smaller biopharmas
Previous Story

Riskcovry, the Insurtech Startup, Secures $4.5M from Morphosis VC

Next Story

Sage Execs Fueling Biotech VC—Meet the Power Duo at Cure Ventures!”

Latest from Blog

CTA Smart secures $3M funding boost

TLDR: CTA Smart, a technology company in the fuel sector, raised US$3M in funding. The funding will be used for expansion into the American market and globally. CTA Smart, a technology company
Go toTop